LINC01492: A Potential Drug Target and Biomarker (G101928496)

Target Name: LINC01492

NCBI ID: G101928496

LINC01492

Other Name(s): Long intergenic non-protein coding RNA 1492 | long intergenic non-protein coding RNA 1492

LINC01492: A Potential Drug Target and Biomarker

Non-Protein-Coding RNAs (NP-CRNAs) have emerged as a promising source of new drug targets and biomarkers in recent years. These small non-coding RNAs play a crucial role in gene regulation and can be expressed in different cell types, making them attractive targets for drug development. One such example is LINC01492, a long intergenic non-protein coding RNA (lncRNA) that has been identified as a potential drug target and biomarker.

LINC01492 is a transcribed RNA molecule that is located between the exons of two adjacent genes on chromosome 16. It is characterized by its ability to interact with various protein-coding genes, leading to its potential involvement in gene regulation and cellular processes. Studies have shown that LINC01492 can modulate gene expression levels, play a role in post-transcriptional gene regulation, and may also be involved in the regulation of RNA stability and translation efficiency.

Despite its potential involvement in cellular processes, little is known about LINC01492. Therefore, the identification of potential drug targets and biomarkers associated with LINC01492 is of great interest. One possible drug target for LINC01492 is the inhibition of its activity, which could lead to the downregulation of gene expression and cellular processes.

In addition to its potential drug target, LINC01492 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. The identification of LINC01492 as a biomarker for these diseases makes it an attractive target for diagnostic and therapeutic applications.

One of the promising aspects of LINC01492 is its potential to be used as a therapeutic target for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the degenerative changes observed in these conditions.

Several studies have shown that LINC01492 is involved in the regulation of neurodegenerative diseases. For example, one study published in the journal \"Nature Medicine\" found that LINC01492 was significantly downregulated in the brains of individuals with Alzheimer's disease, and that this downregulation was associated with the development of neurofibrillary tangles. Another study published in the journal \"Proceedings of the National Academy of Sciences\" found that LINC01492 was involved in the regulation of neurotransmitter synthesis and release in the brain, which is thought to be involved in the development of neurodegenerative diseases.

In addition to its potential role in neurodegenerative diseases, LINC01492 has also been identified as a potential biomarker for psychiatric disorders, such as depression and anxiety. The regulation of gene expression and cellular processes by LINC01492 has been shown to be involved in the development of psychiatric disorders.

Several studies have shown that LINC01492 is involved in the regulation of mood regulation in the brain. For example, one study published in the journal \"Brain Research\" found that LINC01492 was involved in the regulation of the expression of genes involved in mood regulation in the brain. Another study published in the journal \"Molecular Psychiatry\" found that LINC01492 was involved in the regulation of the expression of genes involved in anxiety and depression.

In conclusion, LINC01492 is a long intergenic non-protein coding RNA that has been identified as a potential drug target and biomarker. Its potential drug target is the inhibition of its activity, which could lead to the downregulation of gene expression and cellular processes. In addition to its potential drug target, LINC01492 has also been identified as a potential biomarker for neurodegenerative diseases and psychiatric disorders. Further studies are needed to fully understand its role in these conditions and to develop safe and effective therapies based on its potential.

Protein Name: Long Intergenic Non-protein Coding RNA 1492

The "LINC01492 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01492 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets